IN2012DN00928A - - Google Patents

Info

Publication number
IN2012DN00928A
IN2012DN00928A IN928DEN2012A IN2012DN00928A IN 2012DN00928 A IN2012DN00928 A IN 2012DN00928A IN 928DEN2012 A IN928DEN2012 A IN 928DEN2012A IN 2012DN00928 A IN2012DN00928 A IN 2012DN00928A
Authority
IN
India
Prior art keywords
treatment
relates
benzylideneaminoguanidines
dimethoxybenzylideneamino
guanidine
Prior art date
Application number
Inventor
Niklas Palmqvist
Anders Sjodin
Christina Wenglen
Christofer Flood
Lennart Lundberg
Elisabeth Seifert
Per Lek
Arne Boman
Original Assignee
Anamar Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0913427A external-priority patent/GB0913427D0/en
Priority claimed from GBGB1005495.5A external-priority patent/GB201005495D0/en
Priority claimed from GBGB1010671.4A external-priority patent/GB201010671D0/en
Application filed by Anamar Ab filed Critical Anamar Ab
Publication of IN2012DN00928A publication Critical patent/IN2012DN00928A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention relates to the use of benzylideneaminoguanidines for the treatment of inflammation and pain. In one preferred embodiment, the invention relates to the use of N-(2-chloro-3,4-dimethoxybenzylideneamino)guanidine for the treatment of rheumatoid arthritis.
IN928DEN2012 2009-07-31 2010-07-30 IN2012DN00928A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0913427A GB0913427D0 (en) 2009-07-31 2009-07-31 Compounds for treatment of imflammation
GBGB1005495.5A GB201005495D0 (en) 2010-03-31 2010-03-31 Compounds for treatment of inflammation
GBGB1010671.4A GB201010671D0 (en) 2010-06-24 2010-06-24 Compounds for treatment of inflammation
PCT/GB2010/001457 WO2011012868A1 (en) 2009-07-31 2010-07-30 Compounds for treatment of inflammation

Publications (1)

Publication Number Publication Date
IN2012DN00928A true IN2012DN00928A (en) 2015-04-03

Family

ID=42799430

Family Applications (1)

Application Number Title Priority Date Filing Date
IN928DEN2012 IN2012DN00928A (en) 2009-07-31 2010-07-30

Country Status (13)

Country Link
US (1) US20120190751A1 (en)
EP (1) EP2470270A1 (en)
JP (1) JP2013500957A (en)
CN (1) CN102573993A (en)
AU (1) AU2010277356A1 (en)
BR (1) BR112012002267A2 (en)
CA (1) CA2769541A1 (en)
GB (1) GB2473095A (en)
IN (1) IN2012DN00928A (en)
MX (1) MX2012001144A (en)
NZ (1) NZ598124A (en)
RU (1) RU2012106467A (en)
WO (1) WO2011012868A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3109237A1 (en) 2015-06-22 2016-12-28 AnaMar AB Novel 5-ht2 antagonists
CN105561313B (en) * 2016-01-25 2018-12-25 北京大学 It reduces 5-HT2BR content and its active substance is inhibited to treat and prevent the application in atherosclerosis product in preparation
US11208475B1 (en) * 2018-01-30 2021-12-28 Flagship Pioneering Innovations V, Inc. Methods and compositions for treating inflammatory or autoimmune diseases or conditions using serotonin receptor activators
US20210177814A1 (en) * 2018-05-09 2021-06-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of guanabenz or derivates thereof for the treatment of type i ifn-dependent pathologies

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0520032T3 (en) * 1990-03-16 1999-06-14 Beth Israel Hospital Use of spiperone as an immunosuppressive and anti-inflammatory agent
US5696128A (en) * 1994-07-07 1997-12-09 The Board Of Supervisors Of Louisiana University And Agricultural And Mechanical College Method of regulating immune function
EP0711553A1 (en) * 1994-08-09 1996-05-15 Mario Cagnoni Use of the Melatonin in the traetment of the articular symptoms of trheumatoid arthritis
WO2001025192A1 (en) * 1999-10-06 2001-04-12 Melacure Therapeutics Ab Guanidine derivatives and their use in the production of a medicament for blocking xanthine oxidase/dehydrogenase
GB0019357D0 (en) * 2000-08-07 2000-09-27 Melacure Therapeutics Ab Novel phenyl guanidines
US7060711B2 (en) * 2001-10-25 2006-06-13 Biofrontera Bioscience Gmbh Derivatives of 4-(thio- or selenoxanthene-9-ylidene)-piperidine or acridine and its use as a selective 5-HT2B receptor antagonist
KR20060088885A (en) * 2003-09-25 2006-08-07 아카디아 파마슈티칼스 인코포레이티드 Neuropathic pain treatment method using an agonist of neuropeptide FF receptor 2
GB0623381D0 (en) * 2006-11-23 2007-01-03 Acure Pharma Ab Use of a compound as VEGF inhibitor
GB0701170D0 (en) * 2007-01-22 2007-02-28 Imp Innovations Ltd Compositions and uses thereof
GB0715048D0 (en) * 2007-08-02 2007-09-12 Glaxo Group Ltd Novel compounds
EP2411812B1 (en) * 2009-03-24 2013-10-02 AnaMar AB Metabolic profiles

Also Published As

Publication number Publication date
US20120190751A1 (en) 2012-07-26
RU2012106467A (en) 2013-09-10
JP2013500957A (en) 2013-01-10
WO2011012868A1 (en) 2011-02-03
GB2473095A (en) 2011-03-02
CA2769541A1 (en) 2011-02-03
BR112012002267A2 (en) 2016-11-08
MX2012001144A (en) 2012-05-08
EP2470270A1 (en) 2012-07-04
NZ598124A (en) 2014-01-31
GB201012926D0 (en) 2010-09-15
AU2010277356A1 (en) 2012-03-08
CN102573993A (en) 2012-07-11

Similar Documents

Publication Publication Date Title
EA201491617A1 (en) CONNECTIONS FOR THE TREATMENT OF SPINAL MUSCULAR ATROPHY
MX2009009079A (en) Engineered anti-il-23p19 antibodies.
MX2009009080A (en) Engineered anti-il-23p19 antibodies.
MX2011007930A (en) Crystalline insulin-conjugates.
PH12014501736B1 (en) Therapeutic use of p75ntr neurotrophin binding protein
TN2012000302A1 (en) Oxyntomodulin peptide analogue
MX2009009283A (en) Engineered anti-il-23r antibodies.
MY167920A (en) HUMAN ANTIBODIES TO GFRα3 AND METHODS OF USE THEREOF
MY143269A (en) Use of agomelatine in obtaining medicaments intended for the treatment of generalized anxiety disorder
MX2009011346A (en) Tapentadol for treating pain from arthritis.
DK3363437T3 (en) AMINOIN CODE AND ITS USE IN THE TREATMENT OF PAIN
MY155340A (en) Use of cathepsin c
IN2012DN00928A (en)
HUE047515T2 (en) N-substituted benzenepropanamides for use in the treatment of pain and inflammation
TR200909786A1 (en) Effervescent tablet and granule formulation containing cefixime.
DK2155179T3 (en) Axomadol for pain management arthrosis
IL223065A0 (en) New cathepsin s protease inhibitors, useful in the treatment of e.g. autoimmune disorders, allergy and chronic pain conditions
SG178929A1 (en) Use of cathepsin h
LV14346A (en) 4r,5s-enantiomer of 2-(5-methil-2-oxo-4-phenyl-pyrrolidin-1-yl)-acetamide with nootropic activity
WO2011067189A3 (en) Cmet inhibitors for treating endometriosis
UA110918C2 (en) Inhibitors of protein phosphatase-1 and their use
UA45304U (en) Method for assessment of the patient state with rheumatoid arthritis and efficiency of its treatment
UA50825U (en) Use of antagonist of interleukin-1 receptor as hypouricemic agent
UA52805U (en) Nasal splint
UA106224C2 (en) Crystalline insulin-conjugates